Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-063966
Filing Date
2025-05-06
Accepted
2025-05-06 07:30:14
Documents
81
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q beam-20250331.htm   iXBRL 10-Q 2304510
2 EX-31.1 beam-ex31_1.htm EX-31.1 19402
3 EX-31.2 beam-ex31_2.htm EX-31.2 29409
4 EX-32.1 beam-ex32_1.htm EX-32.1 11442
5 EX-32.2 beam-ex32_2.htm EX-32.2 10618
  Complete submission text file 0000950170-25-063966.txt   10507319

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT beam-20250331.xsd EX-101.SCH 1384804
84 EXTRACTED XBRL INSTANCE DOCUMENT beam-20250331_htm.xml XML 2208159
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39208 | Film No.: 25915243
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)